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Ever since the term “central dogma” was coined in 1958, researchers have sought to con-
trol information flow from nucleic acids to proteins. Talks delivered by Drs. Anna Pyle and
Hiroaki Suga at this year’s Chemical Biology Symposium at Yale in May 2010 applauded re-
cent advances in this area, at the interface between chemistry and biology.
The term “central dogma,” coined by
Dr. Francis Crick in 1958, refers to infor-
mation flow from DNA to messenger RNA
(mRNA†) via transcription, followed by
mRNA translation into protein. The 13th
annual Chemical Biology Symposium at
Yale University in May 2010 highlighted
recent progress in the field, enriching our
understanding of the central dogma and
paving the way for future research at the in-
terface  between  chemistry  and  biology.
Two exciting talks at the symposium ―
one by Dr. Anna Pyle (Yale University) on
self-splicing group II intron RNA and the
other by Dr. Hiroaki Suga (University of
Tokyo) on non-natural peptide synthesis ―
extended our understanding of this dogma.
Most eukaryotic genes are interrupted
by large, non-coding segments known as
introns. Introns are transcribed along with
coding regions but are spliced out before
protein synthesis begins. The task of re-
moving these non-coding sequences from
precursor RNA falls primarily to a large
complex of proteins and RNA known as the
spliceosome. Self-splicing introns, how-
ever, can release themselves from the RNA
molecule  without  the  assistance  of  the
spliceosome. Once removed, these introns
have  the  potential  to  reinsert  into  the
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quence followed by a glycolic acid sequence.genome, altering its structure and organiza-
tion. By self-cutting and pasting, these “ge-
netic parasites,” as Dr. Pyle called them,
may not only facilitate evolutionary change
over time but also may emerge as promising
gene therapy vectors in the future.
To decipher the three-dimensional mo-
lecular architecture of group II introns as well
as their catalytic mechanism, Dr. Pyle’s team
conducted detailed biochemical studies over
many years, including site-specific photo-
cross-linking and Nucleotide Analog Inter-
ference Mapping/Suppression (NAIM/NAIS)
[1,2]. The group accumulated an enormous
amount of data regarding how the RNA is
likely structured, including the interaction
network among domains, a map of atoms
critical for splicing, and the binding positions
of metal ions in the active sites. Finally, Dr.
Pyle’s team successfully crystallized the first
group II intron, purified from Oceanobacil-
lus iheyensis [3], an alkaliphilic eubacterium
inhabiting seabed mud at a depth of 1 km.
The crystal structure of the O. iheyensis in-
tron reveals an elaborate interaction network
fully consistent with decades of biochemical
and genetic studies. Distant domains on the
molecule are interdigitated by tertiary struc-
tural elements, including a z-anchor, a ribose
zipper, a major groove triple helix, and an ʱ-
ʱ’ kissing loop. Additionally, two magnesium
ions sit inside the intron’s catalytic center in
a configuration consistent with a two-metal-
ion mechanism of catalysis. Thus, Dr. Pyle’s
studies greatly elucidate an unconventional
aspect of the central dogma.
For  years,  chemical  biologists  have
been  working  to  incorporate  non-natural
amino acids ― structurally modified amino
acids with different physicochemical and bi-
ological properties ― into proteins. The aim
of this research is to better understand nor-
mal cellular processes, such as posttransla-
tional  modification,  as  well  as  develop
peptides for therapeutic use against targets.
At the symposium, Dr. Suga presented his
work  on  genetic  code  reprogramming,  a
method of addressing this aim. Suga’s group
reassigns codons for natural amino acids to
non-natural amino acids using a flexizyme-
based in vitro translation system. Flexizyme
is a ribozyme that charges transfer RNA
(tRNA) with amino or hydroxy acids ester-
ified with a 3,5-dinitrobenzyle (DBE) group.
Virtually, any amino acid can be charged
onto any desired tRNA since the aminoacy-
lation reaction is independent of the type of
side chain. 
A second component of the experimental
system is a reconstituted, cell-free translation
mixture derived from Escherichia coli. In this
mixture, natural aminoacyl-tRNA synthetases
(ARSs) are removed so their cognate tRNAs
will not be charged. Those uncharged tRNAs,
called vacant codons, are then reassigned to
any desired non-natural amino acid using the
flexizyme system. To maximize the variety
of amino acids in the system, researchers ar-
tificially divide the codon box by taking ad-
vantage of redundancy in the genetic code
(e.g., the codons GUU, GUC, GUA, and
GUG all encode the single amino acid va-
line). For example, GUU and GUC would be
reprogrammed  for  p-methoxyphenyllactic
acid (mFlac), while the GUA and GUG triplets
would still encode valine [4]. 
One proof-of-concept of Dr. Suga’s sys-
tem is the synthesis of backbone-cyclized
peptides [5]. A DNA template encoding a
linear precursor peptide, composed of a cys-
teine-protein dipeptide sequence followed
by a glycolic acid sequence (C-P-HOG), was
in vitro-transcribed and -translated. Expres-
sion of linear peptides bearing the C-P-HOG
sequence resulted in self-rearrangement into
a C-terminal diketopiperadine-thioester. A
cyclized peptide was thus generated non-en-
zymatically, with enhanced structural rigid-
ity,  protcolytic  stability,  and  membrane
permeability. Remarkably, all processes, in-
cluding transcription of the DNA template,
translation of the peptide, and peptide cy-
clization, take place in one reaction tube.
Based on this method, Dr. Suga’s group has
built a library of backbone-cyclized peptides
for rapid screening of peptides or substrate
analogs for inhibition of functionally im-
portant enzymes [6].
Dr. Pyle’s work on group II introns has
clarified their structure and the mechanism
of their removal from the RNA template be-
fore natural protein synthesis. Meanwhile,
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mRNA toward non-natural peptides. These
new discoveries at the interface of chemistry
and biology are furthering our understand-
ing of the central dogma, as well as allowing
us to manipulate it for therapeutic use.
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